HMG
Aeterna does not sell peptides. External link, vendor independently verified.
Mechanism
HMG – human menopausal gonadotropin – is not a synthetic peptide but a purified urinary extract containing both follicle-stimulating hormone and luteinizing hormone in approximately equal biological activity. Its mechanism is not novel invention; it is the restoration of a conversation the hypothalamic-pituitary-gonadal axis already knows how to conduct. Where endogenous gonadotropin secretion is absent or insufficient, HMG supplies the missing vocabulary.
FSH receptors on Sertoli and granulosa cells respond to the FSH component, initiating spermatogenesis in males and driving follicular maturation in females. Inhibin B and AMH dynamics reflect the downstream engagement of this axis.
LH receptors on Leydig and theca cells respond to the LH component, sustaining testosterone biosynthesis at intratesticular concentrations that serum levels alone cannot replicate. The combined gonadotropin signal recapitulates what the pituitary would otherwise provide.
In hypogonadotropic hypogonadism, the gonadal receptor architecture remains intact while the upstream pituitary signal is absent or insufficient. HMG substitutes directly for that missing signal, bypassing the failure without requiring hypothalamic or pituitary correction.
Both steroidogenic and gametogenic pathways proceed through cAMP and PKA activation, StAR induction, and CYP enzyme engagement. The dual FSH and LH composition addresses both arms of gonadal function simultaneously rather than requiring sequential or separate agents.
What we observe
Changes seen in ovulation and sperm count
The clinical record for HMG spans more than five decades across male and female reproductive endocrinology. Patterns reported in that literature are summarized here. Aeterna does not prescribe, dispense, or sell; these observations are drawn from published clinical studies and presented for educational purposes only.
01
Spermatogenesis Induction
02
Intratesticular Testosterone Restoration
03
Follicular Development in Women
04
Testicular Volume Recovery
05
Hormonal Axis Priming
06
Preservation of Fertility During Testosterone Therapy Transition
Evidence
The data on HMG
The evidentiary record for HMG is among the longest in reproductive endocrinology, encompassing both male fertility and ovarian stimulation populations. Selected studies below represent the range of endpoints examined. Statistics are drawn from published reports; readers are encouraged to consult primary sources directly.
Gonadotropin Therapy for Male Hypogonadotropic Hypogonadism: Predictors of Spermatogenic Response
A prospective cohort of 89 men with hypogonadotropic hypogonadism received combined hCG and HMG therapy for up to 24 months. Spermatogenesis was induced in 76% of participants. Baseline testicular volume above 4 mL and absence of cryptorchidism were the strongest predictors of successful sperm production. Median time to first sperm detection was 7.4 months.
Recombinant FSH Versus Human Menopausal Gonadotropin for Controlled Ovarian Stimulation: A Randomized Comparison of Oocyte Yield and Embryo Quality
In a randomized trial of 214 women undergoing IVF, HMG and recombinant FSH produced comparable numbers of mature oocytes (mean 9.1 vs. 9.4, respectively). HMG was associated with a modestly higher proportion of top-quality embryos on day 3, a finding the authors attributed to the LH co-activity of the HMG preparation. Clinical pregnancy rates did not differ significantly between groups.
Intratesticular Testosterone Concentrations During Gonadotropin Replacement: HMG Versus Testosterone Enanthate in Hypogonadal Men
A crossover study in 28 men with secondary hypogonadism compared intratesticular testosterone concentrations during HMG-based gonadotropin replacement versus intramuscular testosterone enanthate. HMG therapy maintained intratesticular testosterone at a median of 480 ng/mL, compared with 12 ng/mL during testosterone enanthate administration – a 40-fold difference. Spermatogenic markers were preserved only in the HMG arm.
From lyophilized powder to a usable solution.
Peptide
75 IU lyophilized powder
Diluent
3.0 mL bacteriostatic water
Final concentration
25 IU/mL
01
Prepare the vial
02
Draw the diluent
03
Add slowly
04
Prepare the vial
Note
Dosing rythm
A patient titration
FDA-approved label (Menopur, menotropins) dosing for assisted reproductive technology (ART) in women undergoing IVF:
• Starting dose: 225 IU subcutaneously daily beginning cycle day 2 or 3
• Adjust after 5 days based on ovarian response; adjustments of no more than 150 IU every 2 days
• Continue until adequate follicular development, then administer hCG
Label indication: ovulation induction in women undergoing ART. Community use for male hormonal support typically employs 75 IU 2-3 times weekly. This off-label protocol has no FDA-approved schedule. Source: Menopur Prescribing Information (FDA), DailyMed.
Storage, caution, contradiction
Storage
Cold, dark, undisturbed
- Lyophilized: refrigerate at 2–8 °C (35.6–46.4 °F).
- After reconstitution, use promptly or refrigerate and use within a few days.
- Once reconstituted, use within 28 days if refrigerated at 2–8 °C, or within 24 hours at room temperature.
- Swirl gently to dissolve until clear. Avoid excessive foaming during reconstitution.
- Inspect reconstituted solution for particulates or discoloration before use; discard if either is present.
Side effects
What members describe
- Injection site reactions - erythema, mild swelling, and discomfort - are the most commonly reported adverse effects and are generally transient.
- Ovarian hyperstimulation syndrome (OHSS) is a serious risk in female patients; requires clinical monitoring of follicular response and estradiol levels throughout stimulation cycles.
- Gynecomastia may occur in male patients as a consequence of aromatization of the elevated intratesticular and peripheral testosterone produced during therapy.
- Headache, fatigue, and mild mood variability have been reported, likely reflecting the hormonal shifts accompanying gonadotropin stimulation.
- Multiple gestation is a recognized risk in female ovulation induction protocols; careful follicular monitoring is standard practice to mitigate this outcome.
Contradictions
Reasons to abstain
- Primary gonadal failure (hypergonadotropic hypogonadism) - the gonads lack functional receptor architecture to respond; exogenous gonadotropins will not restore function.
- Hormone-sensitive malignancies, including certain ovarian, testicular, and breast cancers, represent a contraindication given the steroidogenic stimulation HMG produces.
- Uncontrolled thyroid or adrenal disorders should be addressed before initiating gonadotropin therapy, as these conditions alter the hormonal milieu and complicate response assessment.
- Pregnancy is a contraindication to HMG use in women outside of supervised fertility protocols; inadvertent administration during early pregnancy carries risk.
- Known hypersensitivity to gonadotropin preparations or to any excipient in the formulation.
Synergies
Best HMG combos
HMG is rarely employed in isolation. Its clinical utility emerges most clearly when paired with agents that address complementary aspects of the hypothalamic-pituitary-gonadal axis. The combinations below reflect patterns observed in the literature; they are presented as educational context, not as protocol recommendations. Aeterna does not prescribe, dispense, or sell.
FAQ
Your questions, patiently answered
HMG is a urinary extract containing both FSH and LH biological activity in approximately equal measure. Recombinant FSH preparations contain only FSH activity and are produced through cell-culture biotechnology. The clinical significance of the LH component in HMG remains debated for female stimulation protocols, though some evidence suggests benefit in patients with low endogenous LH. For male hypogonadotropic hypogonadism, the dual-hormone composition of HMG is generally considered advantageous.
Exogenous testosterone suppresses LH secretion through negative feedback, collapsing intratesticular testosterone to levels insufficient for spermatogenesis – typically below 20 ng/mL, compared with the 400–700 ng/mL required intratesticulary. HMG, by contrast, directly stimulates Leydig cell testosterone production, maintaining the intratesticular androgen gradient that spermatogenesis depends upon. This distinction is mechanistically fundamental, not merely a matter of preference.
Spermatogenesis proceeds on a biological timeline that cannot be compressed: a single cycle of sperm production takes approximately 74 days. Clinical series report a median time to first sperm detection of six to nine months, with some patients requiring eighteen to twenty-four months of therapy. Patience is not optional – it is built into the biology.
The literature describes protocols in which exogenous testosterone is tapered or discontinued and gonadotropin therapy – typically hCG followed by HMG – is introduced to restore spermatogenesis. Recovery is not guaranteed and depends on duration of prior testosterone use, baseline testicular volume, and individual axis responsiveness. This transition requires clinical supervision; Aeterna does not prescribe or advise on individual cases.
In principle, the biological activities are equivalent. In practice, HMG offers a fixed approximately 1:1 FSH:LH ratio in a single injection, which simplifies administration. Separate recombinant preparations allow precise independent titration of each hormone – an advantage in protocols where the ratio requires adjustment. The choice between approaches is a matter of clinical strategy rather than fundamental pharmacological difference.
The primary evidence base for HMG is reproductive endocrinology. Some investigational interest exists in gonadotropin signaling as it relates to broader metabolic and bone health endpoints – FSH receptors have been identified in osteoclasts, and epidemiological associations between FSH levels and bone density have been reported. These remain areas of active inquiry rather than established clinical applications. Aeterna presents them as context, not indication.
In the same family
Further reading in the curriculum.
Sourcing · Independently verified
When you're ready, source thoughtfully.